Meeting Banner
Abstract #3221

Clinical viable QSM using accelerated, segmented 3D EPI with inline, automated QSM post-processing

Monique Tourell1,2, Ashley Stewart1,2, Jin Jin2,3,4,5, Sunil Patil6, Kieran O'Brien1,2,3, Simon Robinson1,7,8, and Markus Barth1,2,5
1Centre for Advanced Imaging, University of Queensland, Brisbane, Australia, 2ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland, Brisbane, Australia, 3Siemens Healthcare Pty Ltd, Brisbane, Australia, 4Mark and Mary Stevens Neuroimaging and Informatics Institute, University of Southern California, Los Angeles, CA, United States, 5School of Information Technology and Electrical Engineering, the University of Queensland, Brisbane, Australia, 6Siemens Healthcare Pty Ltd, Malvern, PA, United States, 7High Field Magnetic Resonance Centre, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, 8Department of Neurology, Medical University of Graz, Graz, Austria

Successful translation of QSM into the clinic requires the combination of fast imaging protocols with robust, automated on-scanner processing. In this work we present clinical viable QSM: acquisition of phase data using accelerated, segmented 3D EPI in 30 seconds, and automated QSM post-processing on the scanner in under 2 minutes. The resultant susceptibility maps were of comparable quality to those obtained using a GRE sequence. Analysis of the susceptibilities measured within the caudate, putamen and pallidum demonstrates that 3D EPI with on-scanner processing produces susceptibility values in good agreement with those obtained from a GRE sequence, and offline processing pipelines.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here